BenzingaAugust 10, 2026 at 6:13 AM NY2 Months Ago
Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
